Who are Placebo matching IMU-838 tablets's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-matching-imu-838-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo matching IMU-838 tablets — Competitive Intelligence Brief

Placebo matching IMU-838 tablets (Placebo matching IMU-838 tablets) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective immunomodulator. Area: Immunology.

phase 3 Selective immunomodulator Intracellular signaling (TYK2 and related kinases) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo matching IMU-838 tablets (Placebo matching IMU-838 tablets) — Immunic AG. IMU-838 is a selective immunomodulator that inhibits intracellular signaling pathways to reduce pathogenic immune responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo matching IMU-838 tablets TARGET	Placebo matching IMU-838 tablets	Immunic AG	phase 3	Selective immunomodulator	Intracellular signaling (TYK2 and related kinases)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective immunomodulator class)

Immunic AG · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo matching IMU-838 tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-matching-imu-838-tablets. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab